Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
Allschwil, Switzerland – November 11, 2024
Author Archives: admin
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated…
Company announcement – No. 50 / 2024
Read the rest here:
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated...
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
Global Investments Pave Way for Breakthrough Treatment for Type 2 Diabetes Global Investments Pave Way for Breakthrough Treatment for Type 2 Diabetes
Assertio Reports Third Quarter 2024 Financial Results
Third Quarter Total Net Product Sales of $28.7 Million
See the rest here:
Assertio Reports Third Quarter 2024 Financial Results
Celldex Therapeutics to Present at Upcoming Investor Conferences
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
See the article here:
Celldex Therapeutics to Present at Upcoming Investor Conferences
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET.
Read more:
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update
-- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) ---- 50% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.50 [90% CI, 0.20-1.28]) --
Continue reading here:
Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update
IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that members of its senior management team will participate in the following upcoming investor conferences:
Read the original:
IO Biotech Announces Participation in Upcoming Investor Conferences
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the company will report financial results for the three months ended September 30, 2024, and provide a corporate update on November 18, 2024, at 8:30 a.m. Eastern Time.
See the article here:
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering
Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC” Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC”
Original post:
Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering